MOUNTAIN VIEW, Calif. (AP) ¿ Vivus Inc. on Monday said it moved to a loss in the fourth quarter, as the biopharmaceutical company spent twice as much on research and development as it did a year ago. Most of the development work involved Vivus' lead drug candidate, Qnexa. The company conducting late stage clinical trials of Qnexa for obesity, and mid stage trials as a type 2 diabetes treatment. For the quarter, Vivus reported a loss of $6.7 million, or 10 cents per share. A year ago the company earned $10.4 million, or 17 cents per share. Revenue declined 3 percent to $28.8 million from $29.8 million, as product sales decreased and license revenue was virtually unchanged. Analysts expected the company to break even in the quarter on a per-share basis, and they expected $26.8 million in revenue. Vivus said its research and development costs doubled to $22.7 million in the quarter. It also posted $3.3 million in interest expenses. In 2008, Vivus lost $9.9 million, or 16 cents per share. That compares with a smaller loss of $2.4 million, or 4 cents per share, in 2007. Revenue jumped 87 percent, to $102.2 million from $54.7 million. In aftermarket trading, Vivus shares picked up a penny to $3.05.
More from Technology
Microsoft, Intel and Others Benefit from Better-Than-Expected Business PC Sales
Though CPU shortages are still an issue for the PC industry, an uptick in business PC demand is helping out a number of firms.
Visa, Mastercard, eBay and Stripe All Pull Out of Facebook's Libra
The moves follow PayPal's withdrawal last week.
Amazon Earnings May Not Impress, But Here's Why the Stock Could Still Be a Buy
Amazon Web Services remains a huge bright spot for the stock, analysts say.
SAP's Revenue Growth - and Transparency - Compares Favorably with Oracle's
Unlike archrival Oracle, SAP is reporting solid top-line growth and is comfortable breaking out its cloud revenue.
Okta Eyes Big Enterprises With Security, Access Management Tools
Okta is rolling out a new slate of access management and security offerings. Okta CEO Todd McKinnon discusses the latest developments with TheStreet.